Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis Group
2024-12-01
|
| Schriftenreihe: | Future Science OA |
| Schlagworte: | |
| Online-Zugang: | https://www.tandfonline.com/doi/10.2144/fsoa-2023-0074 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|